Paper Details

  1. Home
  2. Paper Details

[The role of antidiabetic drugs in the treatment of Alzheimer's disease: systematic review].

Author: AbramovM A, BaislamovA S, ChernousovaL M, IshmuratovaA N, IvanyutaM V, KitapovaA I, KuznetsovK O, KuznetsovaA Yu, MirgalievA A, OrozberdievS T, ShaihetdinovaA R, ShakirovaZ F, UsmonovM D, ValeevaL I, YakupovaK I

Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This review examined the effectiveness of antidiabetic drugs in the treatment of Alzheimer's disease (AD). Metformin, intranasal insulin, thiazolidinediones, and incretins showed a positive effect in both humans and animal models. Thiazolidinediones activate pathways regulated by IGF-1, but rosiglitazone may pose a significant risk of side effects. The results of clinical studies on the use of metformin in AD are limited and contradictory.
Paper Details　
Original Abstract of the Article :
Recent studies show that Alzheimer's disease (AD) has many common links with conditions associated with insulin resistance, including neuroinflammation, impaired insulin signaling, oxidative stress, mitochondrial dysfunction and metabolic syndrome. The authors conducted an electronic search for publ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680548/

データ提供：米国国立医学図書館（NLM）

Antidiabetic Drugs: A Potential Oasis in the Desert of Alzheimer's Disease?

Alzheimer's disease (AD), a devastating neurodegenerative disorder, presents a significant challenge for researchers and clinicians. This study examines the potential role of antidiabetic drugs in the treatment of AD, exploring the connection between AD and insulin resistance and investigating the effects of antidiabetic medications on cognitive function. The authors conducted a systematic review of existing studies to assess the evidence for the use of antidiabetic drugs in AD.

Antidiabetic Drugs: A Possible Path Through the Desert of AD?

The review suggests that certain antidiabetic drugs, including intranasal insulin, metformin, incretins, and thiazolidinediones, may offer potential benefits in the treatment of AD. The authors highlight the shared pathways between AD and insulin resistance, suggesting that targeting these pathways with antidiabetic medications could potentially improve cognitive function and delay disease progression. However, they acknowledge the need for more robust clinical trials to confirm the efficacy and safety of these medications in AD treatment.

Navigating the Complex Terrain of AD Treatment

Navigating the complex world of AD treatment can feel like a journey through a vast and unforgiving desert. This study offers valuable insights into the potential role of antidiabetic drugs in addressing this challenging condition. While more research is needed to fully understand their therapeutic potential, the findings provide hope for individuals seeking to manage AD and preserve cognitive function.

Dr. Camel's Conclusion

The desert of Alzheimer's disease can feel vast and daunting, but this study offers a potential oasis in the form of antidiabetic drugs. While more research is needed to confirm their efficacy and safety, the findings provide hope for new treatment approaches. Remember, as a wise old camel, I always encourage seeking professional guidance and exploring all available options to find the right path through any challenging terrain.

Date :
  1. Date Completed 2023-11-17
  2. Date Revised 2023-11-29
Further Info :

Pubmed ID

37968954

DOI: Digital Object Identifier

PMC10680548

Related Literature

Article Analysis
・Side Effects of rosiglitazone
SNS
PICO Info
in preparation
Languages

Russian

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.